Cetilistat is the second pancreatic lipase inhibitor to be developed following orlistat (Xenical). Inpreclinical studies, cetilistat inhibited pancreatic lipase with high selectivity. In short-term (12-week) phase II trials, cetilistat administration to obese individuals, including some with type 2 diabetes, resulted in significant placebo-subtracted weight losses of up to 1.7 kg and small improvements in LDL cholesterol; glycated hemoglobin (HbA1c) levels were reduced in patients with type 2 diabetes.
The magnitude of weight loss produced by cetilistat is similar to other approved antiobesity agents after 12 weeks, moreover the magnitude of weight loss produced by cetilistat is similar to other approved antiobesity agents after 24 weeks.And there is a major putative advantage of cetilistat who has a lower incidence of gastrointestinal adverse events than orlistat.